Literature DB >> 16505659

A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization.

Cristóbal León1, Sergio Ruiz-Santana, Pedro Saavedra, Benito Almirante, Juan Nolla-Salas, Francisco Alvarez-Lerma, José Garnacho-Montero, María Angeles León.   

Abstract

OBJECTIVE: To obtain a score for deciding early antifungal treatment when candidal infection is suspected in nonneutropenic critically ill patients.
DESIGN: Analysis of data collected from the database of the EPCAN project, an ongoing prospective, cohort, observational, multicenter surveillance study of fungal infection and colonization in intensive care unit (ICU) patients.
SETTING: Seventy-three medical-surgical ICUs of 70 teaching hospitals in Spain. PATIENTS: A total of 1,699 ICU patients aged 18 yrs and older admitted for at least 7 days between May 1998 and January 1999 were studied.
INTERVENTIONS: Surveillance cultures of urine, tracheal, and gastric samples were obtained weekly. Patients were grouped as follows: neither colonized nor infected (n=719), unifocal or multifocal Candida colonization (n=883), and proven candidal infection (n=97). The odds ratio (OR) for each risk factor associated with colonization vs. proven candidal infection was estimated. A logistic regression model was performed to adjust for possible confounders. The "Candida score" was obtained according to the logit method. The discriminatory power was evaluated by the area under the receiver operating characteristics curve.
MEASUREMENTS AND MAIN RESULTS: In the logit model, surgery (OR=2.71, 95% confidence interval [CI], 1.45-5.06); multifocal colonization (OR=3.04, 95% CI, 1.45-6.39); total parenteral nutrition (OR=2.48, 95% CI, 1.16-5.31); and severe sepsis (OR=7.68, 95% CI, 4.14-14.22) were predictors of proven candidal infection. The "Candida score" for a cut-off value of 2.5 (sensitivity 81%, specificity 74%) was as follows: parenteral nutrition, +0.908; surgery, +0.997; multifocal colonization, +1.112; and severe sepsis, +2.038. Central venous catheters were not a significant risk factor for proven candidal infection (p=.292).
CONCLUSIONS: In a large cohort of nonneutropenic critically ill patients in whom Candida colonization was prospectively assessed, a "Candida score">2.5 accurately selected patients who would benefit from early antifungal treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505659     DOI: 10.1097/01.CCM.0000202208.37364.7D

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  158 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 2.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 3.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

4.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

Review 5.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  A Risk Score for Fluconazole Failure among Patients with Candidemia.

Authors:  Luis Ostrosky-Zeichner; Rachel Harrington; Nkechi Azie; Hongbo Yang; Nanxin Li; Jing Zhao; Valerie Koo; Eric Q Wu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

7.  On track to limit antifungal overuse!

Authors:  Philippe Eggimann; Frédéric Lamoth; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-02-11       Impact factor: 17.440

8.  Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.

Authors:  Laurence Senn; Philippe Eggimann; Riadh Ksontini; Andres Pascual; Nicolas Demartines; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-01-27       Impact factor: 17.440

Review 9.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

10.  Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.

Authors:  Sébastien Bailly; Elodie Gautier-Veyret; Minh P Lê; Lila Bouadma; Olivier Andremont; Mathilde Neuville; Bruno Mourvillier; Romain Sonneville; Eric Magalhaes; Jordane Lebut; Aguila Radjou; Roland Smonig; Michel Wolff; Laurent Massias; Claire Dupuis; Jean-François Timsit
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.